This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Andrew A.F. Hack net worth and biography

Andrew Hack Biography and Net Worth

Director of Nuvalent

Andrew is a Managing Director of Bain Capital Life Sciences, a private equity fund that invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Previously, Andrew served as Chief Financial Officer of Editas Medicine, Inc.

Prior to joining Editas, Andrew was a portfolio manager at Millennium Management LLC, where he ran a healthcare fund focused on biotechnology, pharmaceutical, and medical device companies. Before joining Millennium, Andrew served as a securities analyst for several healthcare-focused hedge funds and investment banks. Previously, Andrew was Director of Life Sciences of Reify Corporation, a life science tools and drug discovery company.

Andrew serves as a director of Affinivax, Inc., Allena Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc., BCLS Acquisition Corp., Dynavax Technologies, Inc., Imperative Care, Inc., JenaValve Technology, Inc., Mersana Therapeutics, Inc., and Xilio Therapeutics. Andrew received his M.D. and Ph.D. from the University of Chicago in molecular genetics and cell biology.

What is Andrew A.F. Hack's net worth?: The estimated net worth of Andrew A.F. Hack is at least $245.91 million as of March 27th, 2024. Dr. Hack owns 2,697,267 shares of Nuvalent stock worth more than $245,909,832 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Hack may own. Learn More about Andrew A.F. Hack's net worth.
How do I contact Andrew A.F. Hack?: The corporate mailing address for Dr. Hack and other Nuvalent executives is , , . Nuvalent can also be reached via phone at 857-357-7000 and via email at [email protected]. Learn More on Andrew A.F. Hack's contact information.
Has Andrew A.F. Hack been buying or selling shares of Nuvalent?: Andrew A.F. Hack has not been actively trading shares of Nuvalent during the past quarter. Most recently, Andrew A. F. Hack sold 880,000 shares of the business's stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $72.77, for a transaction totalling $64,037,600.00. Following the completion of the sale, the director now directly owns 2,697,267 shares of the company's stock, valued at $196,280,119.59. Learn More on Andrew A.F. Hack's trading history.
Who are Nuvalent's active insiders?: Nuvalent's insider roster includes Alexandra Balcom (CFO), Emily Conley (Director), Andrew Hack (Director), Deborah Miller (insider), Darlene Noci (insider), Henry Pelish (Insider), James Porter (CEO), Matthew Shair (Director), and Christopher Turner (Insider). Learn More on Nuvalent's active insiders.
Are insiders buying or selling shares of Nuvalent?: During the last year, insiders at the sold shares 45 times. They sold a total of 3,575,429 shares worth more than $312,854,115.90. The most recent insider tranaction occured on October, 31st when CFO Alexandra Balcom sold 10,000 shares worth more than $891,900.00. Insiders at Nuvalent own 12.5% of the company. Learn More about insider trades at Nuvalent.
Information on this page was last updated on 10/31/2024.

Andrew A.F. Hack Insider Trading History at Nuvalent

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/27/2024	Sell	880,000	$72.77	$64,037,600.00	2,697,267

Andrew A.F. Hack Buying and Selling Activity at Nuvalent

Nuvalent Company Overview

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $91.17

$90.28

$92.22

50 Day Range

MA: $97.43

$81.68

$112.17

2 Week Range

Now: $91.17

$58.80

$113.51

Volume

264,769 shs

Average Volume

534,697 shs

Market Capitalization

$5.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad